KRS Global Biotechnology 503B State-of-the-Art Facility

UNDER NEW OWNERSHIP AND MANAGEMENT since 2019, KRS Global Biotechnology is an FDA and DEA registered 503B Human Outsourcing Facility that provides sterile intravenous compounded products to hospitals, surgery centers, medical clinics, and medical institutions nationwide

Pain management,hospital products,va medical centers,ambulatory surgery centers,ophthalmic products,ketamine resource,and isoproterenol resource

Krs global biotechnology 503b state-of-the-art facility operates in the Pharmaceutical manufacturing industry.

Krs global biotechnology 503b state-of-the-art facility's revenue is 11m - 100m

Krs global biotechnology 503b state-of-the-art facility has 11 - 50 employees.